DeltaNp63alpha-Mediated Induction of Epidermal Growth Factor Receptor Promotes Pancreatic Cancer Cell Growth and Chemoresistance

Pancreatic ductal adenocarcinoma (PDAC) is highly resistant to current chemotherapy regimens, in part due to alterations in the p53 tumor suppressor pathway. p53 homolog p63 is a transcription factor essential for the development and differentiation of epithelial surfaces. However its function in cancer is controversial and its role in PDAC is not known. We discovered that ΔNp63α was the predominantly expressed p63 variant in pancreatic cancer cell lines. ΔNp63α protein and mRNA levels were high in T3M4, BxPC3 and COLO-357 pancreatic cancer cells and low in ASPC-1 and PANC-1 cells. Overexpression of ΔNp63α in PANC-1 cells and shRNA-mediated knockdown in T3M4 cells indicated that ΔNp63α promoted anchorage-dependent and -independent growth, motility and invasion, and enhanced resistance to cisplatin-induced apoptosis. Epidermal growth factor receptor (EGFR) signaling pathways contribute to the biological aggressiveness of PDAC, and we found that the motogenic effects of ΔNp63α were augmented in presence of EGF. Ectopic expression of ΔNp63α resulted in upregulation of EGFR and β1-integrin in PANC-1 cells. Conversely, ΔNp63α knockdown had an opposite effect in T3M4 cells. ΔNp63α potentiated EGF-mediated activation of ERK, Akt and JNK signaling. Chromatin immunoprecipitation and functional reporter assays demonstrated that ΔNp63α activated EGFR transcription. 14-3-3σ transcription was also positively regulated by ΔNp63α and we have previously shown that 14-3-3σ contributes to chemoresistance in pancreatic cancer cell lines. Conversely, shRNA-mediated knockdown of 14-3-3σ led to abrogation of the ΔNp63α effects on cell proliferation and invasion. Thus, p53 homolog ΔNp63α enhances the oncogenic potential of pancreatic cancer cells through trans-activation of EGFR and 14-3-3σ.

[1]  S. McDade,et al.  p63 maintains keratinocyte proliferative capacity through regulation of Skp2–p130 levels , 2011, Journal of Cell Science.

[2]  T. Ohtsuka,et al.  High EGFR mRNA expression is a prognostic factor for reduced survival in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. , 2011, International journal of oncology.

[3]  H. Vogel,et al.  ΔNp63α is an oncogene that targets chromatin remodeler Lsh to drive skin stem cell proliferation and tumorigenesis. , 2011, Cell stem cell.

[4]  A. Chatterjee,et al.  DeltaNp63alpha confers tumor cell resistance to cisplatin through the AKT1 transcriptional regulation. , 2011, Cancer research.

[5]  Karen H. Vousden,et al.  p53 and its mutants in tumor cell migration and invasion , 2011, The Journal of cell biology.

[6]  Caicun Zhou,et al.  Integrin beta1 over‐expression associates with resistance to tyrosine kinase inhibitor gefitinib in non‐small cell lung cancer , 2010, Journal of cellular biochemistry.

[7]  David A. Cheresh,et al.  Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.

[8]  Milind B. Suraokar,et al.  TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs , 2010, Nature.

[9]  A. Khorana,et al.  Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  M. Korc,et al.  Kinase signaling pathways as targets for intervention in pancreatic cancer , 2010, Cancer biology & therapy.

[11]  A. Chatterjee,et al.  Regulation of p53 family member isoform DeltaNp63alpha by the nuclear factor-kappaB targeting kinase IkappaB kinase beta. , 2010, Cancer research.

[12]  B. Trink,et al.  Loss of DeltaNp63alpha promotes invasion of urothelial carcinomas via N-cadherin/Src homology and collagen/extracellular signal-regulated kinase pathway. , 2009, Cancer research.

[13]  E. Sbisà,et al.  p73 and p63 sustain cellular growth by transcriptional activation of cell cycle progression genes. , 2009, Cancer research.

[14]  S. Lowe,et al.  TAp63 induces senescence and suppresses tumorigenesis in vivo , 2009, Nature Cell Biology.

[15]  T. Jacks,et al.  p63 and p73 Transcriptionally Regulate Genes Involved in DNA Repair , 2009, PLoS genetics.

[16]  P. Coates,et al.  ΔNp63 isoforms differentially regulate gene expression in squamous cell carcinoma: identification of Cox‐2 as a novel p63 target , 2009, The Journal of pathology.

[17]  S. Hanks,et al.  Specific cross-talk between epidermal growth factor receptor and integrin alphavbeta5 promotes carcinoma cell invasion and metastasis. , 2009, Cancer research.

[18]  M. Korc,et al.  14-3-3σ Modulates Pancreatic Cancer Cell Survival and Invasiveness , 2008, Clinical Cancer Research.

[19]  K. Creek,et al.  Loss of p53 induces epidermal growth factor receptor promoter activity in normal human keratinocytes , 2008, Oncogene.

[20]  Jason C. Ho,et al.  The Integrin-Extracellular Matrix Axis in Pancreatic Cancer , 2007, Pancreas.

[21]  L. Ellisen,et al.  p63 and p73 in human cancer: defining the network , 2007, Oncogene.

[22]  P. Murawa,et al.  Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group , 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  D. Sgroi,et al.  The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. , 2007, The Journal of clinical investigation.

[24]  Christopher E Barbieri,et al.  Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. , 2006, Cancer research.

[25]  Jason S. Carroll,et al.  p63 regulates an adhesion programme and cell survival in epithelial cells , 2006, Nature Cell Biology.

[26]  T. Oyama,et al.  Expression of the p53 family in lung cancer. , 2006, Anticancer research.

[27]  Xinbin Chen,et al.  The Unique NH2-terminally Deleted (ΔN) Residues, the PXXP Motif, and the PPXY Motif Are Required for the Transcriptional Activity of the ΔN Variant of p63* , 2006, Journal of Biological Chemistry.

[28]  H. Heng,et al.  Overexpression of Cyclin D1 Promotes Tumor Cell Growth and Confers Resistance to Cisplatin-Mediated Apoptosis in an Elastase-myc Transgene–Expressing Pancreatic Tumor Cell Line , 2005, Clinical Cancer Research.

[29]  R. Hruban,et al.  Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. , 2005, Cancer cell.

[30]  Guojun Wu,et al.  DeltaNp63alpha up-regulates the Hsp70 gene in human cancer. , 2005, Cancer research.

[31]  Guojun Wu,et al.  ΔNp63α Up-Regulates the Hsp70 Gene in Human Cancer , 2005, Cancer Research.

[32]  V. Rao,et al.  Epidermal Growth Factor Receptor-Dependent Regulation of Integrin-Mediated Signaling and Cell Cycle Entry in Epithelial Cells , 2004, Molecular and Cellular Biology.

[33]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[34]  R. DePinho,et al.  Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. , 2003, Genes & development.

[35]  J. Lamb,et al.  Positive and negative regulation of ΔN-p63 promoter activity by p53 and ΔN-p63-α contributes to differential regulation of p53 target genes , 2003, Oncogene.

[36]  Christine A Iacobuzio-Donahue,et al.  Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. , 2003, The American journal of pathology.

[37]  J. Pietenpol,et al.  The ΔNp63α Phosphoprotein Binds the p21 and 14-3-3σ Promoters In Vivo and Has Transcriptional Repressor Activity That Is Reduced by Hay-Wells Syndrome-Derived Mutations , 2003, Molecular and Cellular Biology.

[38]  R. Nenutil,et al.  Differential expression of p63 isoforms in normal tissues and neoplastic cells , 2002, The Journal of pathology.

[39]  M. Korc,et al.  Multiple mitogenic pathways in pancreatic cancer cells are blocked by a truncated epidermal growth factor receptor. , 2002, Cancer research.

[40]  M. Ruge,et al.  Impact of epidermal growth factor (EGF) radioreceptor analysis on long-term survival of gastric cancer patients. , 2002, Anticancer research.

[41]  T. Rikiyama,et al.  p53 Homologue p63 Represses Epidermal Growth Factor Receptor Expression* , 2001, The Journal of Biological Chemistry.

[42]  Xinbin Chen,et al.  p63α and ΔNp63α can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes , 2001, Oncogene.

[43]  J. Jen,et al.  AIS is an oncogene amplified in squamous cell carcinoma. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[44]  H. Vogel,et al.  p63 is a p53 homologue required for limb and epidermal morphogenesis , 1999, Nature.

[45]  M. Rothe,et al.  Bacterial Lipopolysaccharide Activates Nuclear Factor-κB through Interleukin-1 Signaling Mediators in Cultured Human Dermal Endothelial Cells and Mononuclear Phagocytes* , 1999, The Journal of Biological Chemistry.

[46]  O. Potapova,et al.  The Jun Kinase 2 Isoform Is Preferentially Required for Epidermal Growth Factor-Induced Transformation of Human A549 Lung Carcinoma Cells , 1999, Molecular and Cellular Biology.

[47]  A. Yang,et al.  p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. , 1998, Molecular cell.

[48]  R. Iggo,et al.  Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast , 1998, Oncogene.

[49]  H. Friess,et al.  Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. , 1992, The Journal of clinical investigation.

[50]  E. Diamandis,et al.  Pancreatic cancer. , 2013, Clinical chemistry.

[51]  K. Chayama,et al.  Expression of multidrug resistance-associated protein 2 is involved in chemotherapy resistance in human pancreatic cancer. , 2008, International journal of oncology.

[52]  J. Pietenpol,et al.  p53 and Delta Np63 alpha differentially bind and regulate target genes involved in cell cycle arrest, DNA repair and apoptosis. , 2007, Oncogene.

[53]  D. Harmes,et al.  TA-p63-gamma regulates expression of DeltaN-p63 in a manner that is sensitive to p53. , 2006, Oncogene.

[54]  Xinbin Chen,et al.  The unique NH2-terminally deleted (DeltaN) residues, the PXXP motif, and the PPXY motif are required for the transcriptional activity of the DeltaN variant of p63. , 2006, The Journal of biological chemistry.

[55]  L. Ellisen,et al.  p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. , 2006, Cancer cell.

[56]  J. Pietenpol,et al.  The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. , 2003, Molecular and cellular biology.

[57]  J. Lamb,et al.  Positive and negative regulation of deltaN-p63 promoter activity by p53 and deltaN-p63-alpha contributes to differential regulation of p53 target genes. , 2003, Oncogene.

[58]  M. Dohn,et al.  p63alpha and DeltaNp63alpha can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. , 2001, Oncogene.

[59]  H. Friess,et al.  Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. , 1993, Anticancer research.

[60]  R. L. Baldwin,et al.  Growth inhibition of human pancreatic carcinoma cells by transforming growth factor beta-1. , 1993, Growth factors.